AP31969 / Acesion - LARVOL DELTA

END-AF-1: Clinical Randomised Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Acesion Pharma

New P2 trial • Atrial Fibrillation • Cardiovascular

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969 (clinicaltrials.gov) - P1 | N=92 | Completed | Sponsor: Acesion Pharma | Recruiting ➔ Completed

Trial completion

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study with AP31969 (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Acesion Pharma | Trial completion date: Sep 2024 ➔ Feb 2025 | Trial primary completion date: Sep 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969 (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Acesion Pharma | Trial completion date: May 2024 ➔ Sep 2024 | Trial primary completion date: May 2024 ➔ Sep 2024

Trial completion date • Trial primary completion date

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969 (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Acesion Pharma | Not yet recruiting ➔ Recruiting

Enrollment open

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969 (clinicaltrials.gov) - P1 | N=124 | Not yet recruiting | Sponsor: Acesion Pharma

New P1 trial